Clinical Trial: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07262164) titled 'A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors' on Nov. 16.

Brief Summary: VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2062, and recommended dose of VG2062 for Phase II trials.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Solid...